Navigation Links
FDA Approves Botox to Treat Chronic Migraine
Date:10/15/2010

SILVER SPRING, Md., Oct. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine. Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)  

"Chronic migraine is one of the most disabling forms of headache," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "Patients with chronic migraine experience a headache more than 14 days of the month. This condition can greatly affect family, work, and social life, so it is important to have a variety of effective treatment options available."

Migraine headaches are described as an intense pulsing or throbbing pain in one area of the head. The headaches are often accompanied by nausea, vomiting, and sensitivity to light and sound. Migraine is three times more common in women than in men. Migraine usually begins with intermittent headache attacks 14 days or fewer each month (episodic migraine), but some patients go on to develop the more disabling chronic migraine.

To treat chronic migraines, Botox is given approximately every 12 weeks as multiple injections around the head and neck to try to dull future headache symptoms. Botox has not been shown to work for the treatment of migraine headaches that occur 14 days or less per month, or for other forms of headache. It is important that patients discuss with their physician whether Botox is appropriate for them.

The most common adverse reactions reported by patients being treated for chronic migraine were n
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today announced that Robert ... Directors. "Bob is an ardent champion for innovation ... privilege to have him on Edwards, board as we pursue ... Edwards, chairman and CEO.  "Bob has provided a valuable perspective ...
(Date:7/30/2015)... SAN DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... ended June 30, 2015.  Revenue for the quarter was ... quarter ended June 30, 2014 (a 17 percent increase ... million, consistent with the quarter ended June 30, 2014. ... consistent with the quarter ended June 30, 2014.  ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... , ST. LOUIS , Feb. 3 ... of Directors declared a quarterly dividend of $0.04 ... shareholders of record on February 15, 2010 . , ... by dentists, dental hygienists, dental assistants, and consumers. The Company,s ...
... , SAN DIEGO , Feb. 3 BD ... BDX ), today announced the launch of the Be ... of influenza. Recognizing that schools and hospitals are important centers for ... designed to communicate that everyone can help prevent the spread of ...
Cached Medicine Technology:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend 2BD Launches 'Be a Flu Fighter' Campaign to Promote Influenza Awareness and Prevention in Schools, Hospitals and Laboratories 2
(Date:7/31/2015)... Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... surgeons and cosmetic experts gathered to see if they could reach a consensus on ... including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and potential patients alike on various plastic surgery procedures including, but not limited ... such popular dermatology procedures like Botox and fillers. , Staying up to ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Transfinder, a software ... , Total sales were up 16 percent year-over-year for the first six months ended ... Civitella said he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Girl Scouts of ... bullying across Georgia through the Girl Scout "Be a Friend First" program. Representatives from ... July 30. , “Peach State Health Plan and our parent company, Centene Corporation, ...
(Date:7/31/2015)... ... ... The 2015 ALS Ice Bucket Challenge will officially get underway today at ... Ice Bucket co-founders Pat Quinn and Pete Frates, the ALS community and Lou Gehrig’s ... the ALS organizations to find treatments and cures for the disease. , ALS ...
Breaking Medicine News(10 mins):Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4
... current,issue of the journal Public Health Reports examines the potential ... dental amalgam, a material,commonly used to fill cavities. The authors ... $8.2 billion in the first year alone -- a,staggering 10 ... available as a treatment option. Dental amalgam contains a ...
... dog new tricks: antimalarial prevents cancer in mice ... from St Jude Childrens Research Hospital, Memphis, and Scripps ... chloroquine effectively prevents cancer in mouse models of two ... As discussed in the accompanying commentary by Chi Dang, ...
... 20, 2007 In one of the largest studies of ... Public Health assessed the risk of exposure to bloodborne pathogens ... one out of 10 of the more than 1100 nurse ... 12 months. Findings of the study are published in ...
... the structure of a DNA-protein complex that is crucial in ... also provides fundamental insight into how cells successfully divide into ... in the Dec. 20th issue of Nature focuses on how ... Using X-ray crystallography, the team led by structural biologists at ...
... Cardiovascular disease (CVD) death rates are declining, but CVD ... the United States, and risk factor control remains a ... from the American Heart Associations Heart Disease and Stroke ... available in the Dec. 17 online issue of Circulation: ...
... One small water line feeding one hospital ... Legionella expert Janet Stout, Ph.D., urging public health and ... other waterborne microbes that contribute to soaring hospital infection ... can line every pipe in every water distribution system ...
Cached Medicine News:Health News:Banning Amalgam Could Increase U.S. Dental Costs by $8 Billion a Year 2Health News:JCI table of contents: Dec. 20, 2007 2Health News:JCI table of contents: Dec. 20, 2007 3Health News:JCI table of contents: Dec. 20, 2007 4Health News:JCI table of contents: Dec. 20, 2007 5Health News:JCI table of contents: Dec. 20, 2007 6Health News:JCI table of contents: Dec. 20, 2007 7Health News:JCI table of contents: Dec. 20, 2007 8Health News:Nonhospital health-care workers at substantial risk of exposure to bloodborne pathogens 2Health News:Nonhospital health-care workers at substantial risk of exposure to bloodborne pathogens 3Health News:Researchers solve first structure of a key to intact DNA inheritance 2Health News:Researchers solve first structure of a key to intact DNA inheritance 3Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 2Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 3Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 4Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 5Health News:Making hospitals safer from infection 2
These are coronary angiographic catheters used for selective coronary bypass angiography. The catheters curve configuration is ideally suited to select the internal mammary artery....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... complete offering of cardiology catheters. Available in ... are designed with excellent torque, new wire-braid ... push-ability, and large inner lumens for excellent ... and 7 French sizes with pressure ratings ...
Medicine Products: